Untargeted metabonomic analysis of non-alcoholic fatty liver disease with iron overload in rats via UPLC/MS

References

• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi: 10.1002/hep.28431.
   PubMed Web of Science ®Google Scholar
• Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39(1):328–348. doi: 10.1002/med.21515.
   PubMed Web of Science ®Google Scholar
• Mundi MS, Velapati S, Patel J, et al. Evolution of NAFLD and its management. Nutr Clin Pract. 2020;35(1):72–84. doi: 10.1002/ncp.10449.
   PubMed Web of Science ®Google Scholar
• Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49(2):197–211. doi: 10.1080/03602532.2017.1293683.
   PubMed Web of Science ®Google Scholar
• Alonso C, Fernández-Ramos D, Varela-Rey M, et al. Metabolomic identification of subtypes of nonalcoholic steatohepatitis. Gastroenterology. 2017;152(6):1449–1461.e7. doi: 10.1053/j.gastro.2017.01.015.
   PubMed Web of Science ®Google Scholar
• Wang C-Y, Babitt JL. Liver iron sensing and body iron homeostasis. Blood. 2019;133(1):18–29. doi: 10.1182/blood-2018-06-815894.
   PubMed Web of Science ®Google Scholar
• Milic S, Mikolasevic I, Orlic L, et al. The role of iron and iron overload in chronic liver disease. Med Sci Monit. 2016;22:2144–2151. doi: 10.12659/msm.896494.
   PubMed Web of Science ®Google Scholar
• Muñoz M, García-Erce JA, Remacha AF. Disorders of iron metabolism. Part 1: molecular basis of iron homoeostasis. J Clin Pathol. 2011;64(4):281–286. doi: 10.1136/jcp.2010.079046.
   PubMed Web of Science ®Google Scholar
• Datz C, Müller E, Aigner E. Iron overload and non-alcoholic fatty liver disease. Minerva Endocrinol. 2017;42(2):173–183. doi: 10.23736/s0391-1977.16.02565-7.
   PubMed Web of Science ®Google Scholar
• Handa P, Thomas S, Morgan-Stevenson V, et al. Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis. J Leukoc Biol. 2019;105(5):1015–1026. doi: 10.1002/jlb.3a0318-108r.
   PubMed Web of Science ®Google Scholar
• Mehta KJ, Farnaud SJ, Sharp PA. Iron and liver fibrosis: mechanistic and clinical aspects. World J Gastroenterol. 2019;25(5):521–538. doi: 10.3748/wjg.v25.i5.521.
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Lindon JC, Holmes E. Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29(11):1181–1189. doi: 10.1080/004982599238047.
   PubMed Web of Science ®Google Scholar
• Lu W, Su X, Klein MS, et al. Metabolite measurement: pitfalls to avoid and practices to follow. Annu Rev Biochem. 2017;86:277–304. doi: 10.1146/annurev-biochem-061516-044952.
   PubMed Web of Science ®Google Scholar
• Perakakis N, Stefanakis K, Mantzoros CS. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism. 2020;111s:154320. doi: 10.1016/j.metabol.2020.154320.
   PubMedGoogle Scholar
• Loomba R, Kayali Z, Noureddin M, et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology. 2018;155(5):1463–1473.e6. doi: 10.1053/j.gastro.2018.07.027.
   PubMed Web of Science ®Google Scholar
• Rom O, Liu Y, Liu Z, et al. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Sci Transl Med. 2020;12(572):az2841 10.1126/scitranslmed.aaz2841.
   Web of Science ®Google Scholar
• Clifford BL, Sedgeman LR, Williams KJ, et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. 2021;33(8):1671–1684.e4. doi: 10.1016/j.cmet.2021.06.012.
   PubMed Web of Science ®Google Scholar
• Zeybel M, Altay O, Arif M, et al. Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients. Mol Syst Biol. 2021;17(10):e10459. doi: 10.15252/msb.202110459.
   PubMed Web of Science ®Google Scholar
• Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021;70(4):761–774. doi: 10.1136/gutjnl-2019-319664.
   PubMed Web of Science ®Google Scholar
• Sinha K, Das J, Pal PB, et al. Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch Toxicol. 2013;87(7):1157–1180. doi: 10.1007/s00204-013-1034-4.
   PubMed Web of Science ®Google Scholar
• Cichoż-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. World J Gastroenterol. 2014;20(25):8082–8091. doi: 10.3748/wjg.v20.i25.8082.
   PubMed Web of Science ®Google Scholar
• Lugo-Huitrón R, Blanco-Ayala T, Ugalde-Muñiz P, et al. On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol. 2011;33(5):538–547. doi: 10.1016/j.ntt.2011.07.002.
   PubMed Web of Science ®Google Scholar
• Christen S, Peterhans E, Stocker R. Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases. Proc Natl Acad Sci USA. 1990;87(7):2506–2510. doi: 10.1073/pnas.87.7.2506.
   PubMed Web of Science ®Google Scholar
• López-Burillo S, Tan DX, Mayo JC, et al. Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and alpha-lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: a study of their individual and synergistic actions. J Pineal Res. 2003;34(4):269–277. doi: 10.1034/j.1600-079x.2003.00041.x.
   PubMed Web of Science ®Google Scholar
• Roumeliotis S, Roumeliotis A, Dounousi E, et al. Dietary antioxidant supplements and uric acid in chronic kidney disease: a review. Nutrients. 2019;11(8):1911. doi: 10.3390/nu11081911.
   PubMed Web of Science ®Google Scholar
• Krähenbühl L, Reichen J, Talos C, et al. Benzoic acid metabolism reflects hepatic mitochondrial function in rats with long-term extrahepatic cholestasis. Hepatology. 1997;25(2):278–283. doi: 10.1053/jhep.1997.v25.pm0009021934.
   PubMed Web of Science ®Google Scholar
• Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47(2):241–259. doi: 10.1194/jlr.R500013-JLR200.
   PubMed Web of Science ®Google Scholar
• Chow MD, Lee Y-H, Guo GL. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med. 2017;56:34–44. doi: 10.1016/j.mam.2017.04.004.
   PubMed Web of Science ®Google Scholar
• Faubion WA, Guicciardi ME, Miyoshi H, et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest. 1999;103(1):137–145. doi: 10.1172/jci4765.
   PubMed Web of Science ®Google Scholar
• Rodrigues CM, Fan G, Wong PY, et al. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med. 1998;4(3):165–178. doi: 10.1007/BF03401914.
   PubMed Web of Science ®Google Scholar
• Spivey JR, Bronk SF, Gores GJ. Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium. J Clin Invest. 1993;92(1):17–24. doi: 10.1172/jci116546.
   PubMed Web of Science ®Google Scholar
• Rodrigues CM, Fan G, Ma X, et al. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest. 1998;101(12):2790–2799. doi: 10.1172/jci1325.
   PubMed Web of Science ®Google Scholar
• Lent BA, Kim KH. Phosphorylation and activation of acetyl-coenzyme a carboxylase kinase by the catalytic subunit of cyclic AMP-dependent protein kinase. Arch Biochem Biophys. 1983;225(2):972–978. doi: 10.1016/0003-9861(83)90113-3.
   PubMed Web of Science ®Google Scholar
• Herzig S, Hedrick S, Morantte I, et al. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma. Nature. 2003;426(6963):190–193. doi: 10.1038/nature02110.
   PubMed Web of Science ®Google Scholar
• Herzig S, Long F, Jhala US, et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001;413(6852):179–183. doi: 10.1038/35093131.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhao M, Sud N, et al. Glucagon regulates hepatic lipid metabolism via cAMP and insig-2 signaling: implication for the pathogenesis of hypertriglyceridemia and hepatic steatosis. Sci Rep. 2016;6:32246. doi: 10.1038/srep32246.
   PubMed Web of Science ®Google Scholar
• Meléndez-Hevia E, Waddell TG, Cascante M. The puzzle of the Krebs citric acid cycle: assembling the pieces of chemically feasible reactions, and opportunism in the design of metabolic pathways during evolution. J Mol Evol. 1996;43(3):293–303. doi: 10.1007/bf02338838.
   PubMed Web of Science ®Google Scholar
• Carrari F, Urbanczyk-Wochniak E, Willmitzer L, et al. Engineering Central metabolism in crop species: learning the system. Metab Eng. 2003;5(3):191–200. doi: 10.1016/s1096-7176(03)00028-4.
   PubMed Web of Science ®Google Scholar
• Wang H, Liu C, Zhao Y, et al. Mitochondria regulation in ferroptosis. Eur J Cell Biol. 2020;99(1):151058. doi: 10.1016/j.ejcb.2019.151058.
   PubMed Web of Science ®Google Scholar
• Leong SC, Sirich TL. Indoxyl sulfate-review of toxicity and therapeutic strategies. Toxins. 2016;8(12):358. doi: 10.3390/toxins8120358.
   PubMed Web of Science ®Google Scholar
• Opdebeeck B, Maudsley S, Azmi A, et al. Indoxyl sulfate and p-Cresyl sulfate promote vascular calcification and associate with glucose intolerance. J Am Soc Nephrol. 2019;30(5):751–766. doi: 10.1681/ASN.2018060609.
   PubMed Web of Science ®Google Scholar
• Luce M, Bouchara A, Pastural M, et al. Is 3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) a clinically relevant uremic toxin in haemodialysis patients? Toxins. 2018;10(5):205. doi: 10.3390/toxins10050205.
   PubMed Web of Science ®Google Scholar
• Prentice KJ, Luu L, Allister EM, et al. The furan fatty acid metabolite CMPF is elevated in diabetes and induces β cell dysfunction. Cell Metab. 2014;19(4):653–666. doi: 10.1016/j.cmet.2014.03.008.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wang Y, Ong CN, et al. Metabolic signatures and risk of type 2 diabetes in a Chinese population: an untargeted metabolomics study using both LC-MS and GC-MS. Diabetologia. 2016;59(11):2349–2359. doi: 10.1007/s00125-016-4069-2.
   PubMed Web of Science ®Google Scholar
• Jitrapakdee S. Transcription factors and coactivators controlling nutrient and hormonal regulation of hepatic gluconeogenesis. Int J Biochem Cell Biol. 2012;44(1):33–45. doi: 10.1016/j.biocel.2011.10.001.
   PubMed Web of Science ®Google Scholar
• Yajima H, Komatsu M, Schermerhorn T, et al. cAMP enhances insulin secretion by an action on the ATP-sensitive K + channel-independent pathway of glucose signaling in rat pancreatic islets. Diabetes. 1999;48(5):1006–1012. doi: 10.2337/diabetes.48.5.1006.
   PubMed Web of Science ®Google Scholar